Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -0.99% 25.00 24.50 25.50 25.50 25.00 25.25 546,520 09:07:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -2.7 -0.3 - 16

Valirx Share Discussion Threads

Showing 23801 to 23824 of 24100 messages
Chat Pages: 964  963  962  961  960  959  958  957  956  955  954  953  Older
DateSubjectAuthorDiscuss
30/11/2020
09:15
To be honest I expected a better share price reaction than this. But anyway I hold and hopefully a deal happens in the near future.
jungmana
30/11/2020
09:05
I agree Bossman, the authorities have forgotten the meaning of the word efficacy!
tburns
30/11/2020
08:43
After more than 10yrs and still no USA FDA appoval etc nor in the UK..But we have 3 vaccines for covid19 in less than a year????
thebossman
30/11/2020
08:40
Subdued reaction considering potential treatment for prostate cancer BUT not for long especially if a jv done and do not think it will be long now!!!
joeblogg2
30/11/2020
08:36
Boom....lift off.... fizzle ...fizzle...oopphhs....oh dear.
forkie 12
30/11/2020
08:34
Lots of deals to be done off the back of this looking forward to the webcast on the 8the. No rationale reason why this wont test recent highs if 70p by Xmas. GLA
tburns
30/11/2020
08:31
Haven't seen nico here for a while, has he sold?
jungmana
30/11/2020
08:28
Nice to see that Burnley are looking likely to return to the tier where they belong
forkie 12
30/11/2020
08:26
The important bit is how it is received by the market and therefore reflected in the share price.......or as in this case NOT. Same old rubbish from desperate loser ramper ...uncanny really.
forkie 12
30/11/2020
08:26
Happy days to come.
412069
30/11/2020
08:21
The important bit i.e. JV deal:"We continue to share the dataset with potential industry partners who expressed an interest after the headline results were released in September 2020, and I look forward to the discussions that I am confident will arise as we evaluate all options for further clinical development."
wulber
30/11/2020
08:15
Update... 30 November 2020 ("ValiRx", the "Company" or the "Group") VAL201 Clinical Trial Full Data Results Full dataset confirms VAL201 is a safe and well-tolerated drug candidate Company to host webcast for investors on 8 December 2020 at 2 pm GMT London, UK - ValiRx plc ("ValiRx", AIM:VAL), a clinical stage drug development company, is pleased to report that it has received the full dataset to be used for the Clinical Study Report from the Phase 1/2 clinical trial of its lead asset, VAL201, for the treatment of locally advanced or metastatic prostate cancer and performed at University College Hospital (UCLH), London. This expands the positive headline results announced on 28 September 2020. The dataset provides a complete breakdown of the full data of safety and tolerability as well as evidence for encouraging disease impact as observed during the clinical trial. This data will be used to formulate the Clinical Study Report and to report the results on the www.clinicaltrials.gov database. Additional detailed analysis of the results will form the basis of peer-reviewed journal publications. The full dataset is available to download on the Company website, hxxps://www.valirx.com/our-pipeline/val201 . Key details of the findings: Recruitment Criteria -- Twelve patients were recruited according to the criteria of having incurable, locally advanced or metastatic prostate cancer with rising PSA[1] (Prostate-Specific Antigen) on three consecutive samples and absent or very mild prostate cancer-related symptoms. -- The demographics and a detailed breakdown of the patients recruited is provided in the download. Disease Impact -- The headline results released in the Company announcement on 28 September 2020 highlighted the response rate of 54.5%, where response was confirmed by a lack of disease progression by PCWG2 (Prostate Cancer Working Group 2) criteria. The dataset now received provides the detailed breakdown of this by providing both the PSA modulation afforded by the treatment, and the tumour response. -- The PSA data, a recognised surrogate of disease progression, shows two patients seeing a decrease in PSA during their treatment period, one of which maintained the decrease throughout the trial. An analysis of the doubling time of patients shows a statistically significant (p<0.05, two-tailed Wilcoxon Signed-Rank test for paired samples) increase in PSA doubling time comparing pre-treatment doubling time to post-treatment doubling time. The PSA doubling time would be expected to be unchanged if the treatment was having no impact, so an increase in doubling time demonstrates a slowing rate of growth of PSA levels. -- The tumour response data demonstrates that patients did not have an increase in metastatic lesions during the treatment period, and that metastatic lesions already present did not grow at all in two out of three patients, suggesting a positive influence of VAL201 on the disease. Safety and Tolerability The further breakdown of the safety data confirms the well tolerated nature of the drug. Additionally, the initial pharmacokinetic analysis supports the safety profile in confirming the drug is processed and cleared from the body in the manner expected. The Company expects to publish the data on the National Institute of Health's (NIH) public database ClinicalTrials.gov, as well as produce research papers for peer-reviewed publications. Investor Webcast ValiRx will host a webcast for investors on Tuesday, 8 December 2020 at 2pm GMT to discuss the findings of the study.
thebossman
30/11/2020
08:15
Expect deals soon imo:"We continue to share the dataset with potential industry partners who expressed an interest after the headline results were released in September 2020, and I look forward to the discussions that I am confident will arise as we evaluate all options for further clinical development. We would like to thank the team for their hard work and our shareholders for their support."
jungmana
30/11/2020
08:15
Great news!!!"We continue to share the dataset with potential industry partners who expressed an interest after the headline results were released in September 2020, and I look forward to the discussions that I am confident will arise as we evaluate all options for further clinical development. We would like to thank the team for their hard work and our shareholders for their support."
joeblogg2
30/11/2020
08:00
We must be worth 4 to 6 times todays market cap imo after such excellent full 201 results
jungmana
30/11/2020
07:56
I know we're excited that we're about to make a shed load of money, but let's spare a thought for the test cases. Let's hope Val gives these guys a Merry Christmas too.
hodhasharon
30/11/2020
07:55
£1 anyone ?
readdin
30/11/2020
07:54
BOOM BOOM BOOM......£1 VAL for Christmas. Thank you God!
hodhasharon
30/11/2020
07:52
Excellent!
jungmana
30/11/2020
07:49
Boom time !
reidy66
29/11/2020
09:26
Yes, I am hopeful that in this case it is a case of Blue Monday after the Q&A is released and not a case of I dont like Mondays...
lagansider
29/11/2020
09:04
Let's hope it's a good monday
rosco230667
27/11/2020
13:23
Plus this months Q&A looking like Monday now.
412069
27/11/2020
12:46
Results still on targets due Q4 201
jasonpugh
Chat Pages: 964  963  962  961  960  959  958  957  956  955  954  953  Older
ADVFN Advertorial
Your Recent History
LSE
VAL
Valirx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210125 14:54:05